Core Viewpoint - The Shanghai Composite Index experienced a rebound, moving into positive territory after previously declining over 0.35%, while the Shenzhen Component Index and the ChiNext Index fell by 0.42% and 0.48% respectively [1] Industry Summary - The sectors showing the most significant gains included recombinant proteins, combustible ice, and brain engineering [1]

Group 1 - The restructuring protein concept declined by 1.06%, ranking among the top declines in concept sectors, with *ST WanFang hitting the limit down [1] - Within the restructuring protein sector, major declines were seen in He Yuan Bio, San Sheng Guo Jian, and Hua Xi Bio, while 15 stocks experienced price increases, with InnoTech, Dezheng Health, and Ao Pu Mai leading the gains at 1.72%, 1.36%, and 1.33% respectively [1][2] Group 2 - The restructuring protein sector saw a net outflow of 542 million yuan from main funds, with 33 stocks experiencing outflows, and 13 stocks seeing outflows exceeding 10 million yuan [2] - He Yuan Bio had the highest net outflow of 277 million yuan, followed by Rejing Bio, Hua Xi Bio, and Hua Lan Bio with net outflows of 38.27 million yuan, 34.39 million yuan, and 32.92 million yuan respectively [2][3] Group 3 - The top stocks with net inflows in the restructuring protein sector included Jianyou Co., Xilong Science, and Borui Pharmaceutical, with net inflows of 17.18 million yuan, 13.67 million yuan, and 8.93 million yuan respectively [4]

Market Overview - The Asia-Pacific stock markets experienced a collective decline influenced by the "Black Tuesday" in the US stock market, but the A-shares showed an independent trend with all three major indices closing higher. The Shanghai Composite Index rose by 0.23% to 3969 points, the Shenzhen Component Index increased by 0.37%, and the ChiNext Index gained 1.03% [1]. Trading Volume and Market Activity - The total market turnover reached 1.89 trillion yuan, a decrease of 441 billion yuan compared to the previous trading day, with nearly 3400 stocks rising [1]. Sector Performance - The Hainan sector was notably active, with stocks like Haima Automobile and Haixia Shares hitting the daily limit. The State Grid completed fixed asset investments exceeding 420 billion yuan, leading to gains in the electric grid equipment, ultra-high voltage, and smart grid sectors, with stocks such as Jinguan Electric and TBEA also hitting the daily limit [1]. - The titanium dioxide sector saw a surge, with Vanadium Titanium Shares hitting the daily limit. The photovoltaic equipment sector also performed well, with Aters hitting a 20% increase limit. Other sectors with significant gains included duty-free concepts, high-speed charging, energy storage, and wind power equipment [1]. Declining Sectors - The recombinant protein sector declined, with Sanofi falling over 8%. The quantum technology sector also saw a drop, with Keda Guokai decreasing by over 7%. Other sectors that experienced significant declines included Kimi concept, data security, digital currency, and CRO [1]. Top Gainers - The top gainers included sectors such as forestry, power generation equipment, and electrical grid, with respective increases of 3.88%, 1.68%, and 3.43% [2].

Investment Rating - The report does not explicitly provide an investment rating for the industry Core Insights - The market experienced a volume contraction on October 31, 2025, with the lithium battery sector maintaining its strong performance. The Shanghai Composite Index fell by 0.81%, the Shenzhen Component Index decreased by 1.14%, and the ChiNext Index dropped by 2.31%. The total market turnover was 23,498.12 billion yuan, a decrease of 1,144.82 billion yuan from the previous trading day. A total of 3,760 stocks rose while 1,553 stocks fell [2][15] Market Performance Summary - On October 31, 2025, the market saw a mixed performance across various indices, with the consumer sector outperforming others. The turnover in the market was significantly lower compared to the previous day, indicating a cautious sentiment among investors [15][21] - The performance of major indices was as follows: Shanghai Composite Index at 3,954.79, Shenzhen Component Index at 13,378.21, and ChiNext Index at 3,187.53, with respective declines of 0.81%, 1.14%, and 2.31% [19] Industry Performance Summary - Among the 30 first-level industries, the media sector led with a gain of 2.49%, followed closely by consumer services at 2.45% and pharmaceuticals at 2.37%. Conversely, the telecommunications sector saw a decline of 4.19%, followed by electronics at -2.84% and non-ferrous metals at -1.98% [21][24] Fund Flow Performance - On October 31, 2025, the main funds experienced a net outflow of 629.03 billion yuan, with large orders contributing significantly to this outflow. However, small orders saw a continuous net inflow of 684.43 billion yuan, indicating a shift in investor behavior [3][25] - Southbound funds recorded a net inflow of 87.19 billion HKD, with the Shanghai-Hong Kong Stock Connect contributing 57.72 billion HKD and the Shenzhen-Hong Kong Stock Connect contributing 29.47 billion HKD [4][27] ETF Performance Summary - The trading volume of major ETFs such as the Huaxia Shanghai 50 ETF and the Huatai-PB CSI 300 ETF increased significantly compared to the previous trading day, indicating a positive sentiment towards these funds [29]

Core Viewpoint - The recombinant protein concept has seen a significant increase of 3.72%, leading the sector in gains, with notable stocks such as Sangamo Therapeutics and ST Wan Fang reaching their daily limit up [1][2]. Group 1: Market Performance - The recombinant protein sector had 50 stocks rising, with Sangamo Therapeutics hitting a 20% limit up, followed by Zai Lab and others with gains of 16.14%, 13.07%, and 12.33% respectively [1]. - The top decliners included Haoyuan Pharmaceutical, Kefu Medical, and Marubi Biotechnology, which fell by 5.89%, 4.35%, and 4.16% respectively [1]. Group 2: Capital Flow - The recombinant protein sector attracted a net inflow of 527 million yuan, with 26 stocks receiving net inflows, and 8 stocks exceeding 30 million yuan in net inflow [2]. - The leading stock in terms of net inflow was C He Yuan, with a net inflow of 187 million yuan, followed by Sangamo Therapeutics and Maiwei Biotechnology with net inflows of 132 million yuan and 126 million yuan respectively [2][3]. Group 3: Stock Performance Metrics - The top stocks by net inflow ratio included Sangamo Therapeutics at 16.55%, Maiwei Biotechnology at 12.96%, and C He Yuan at 9.88% [3]. - The trading volume and turnover rates for key stocks were notable, with C He Yuan showing a turnover rate of 37.86% and Sangamo Therapeutics at 1.87% [3][4].

Core Viewpoint - The Tonghuashun Fruit Index concept has experienced a decline of 2.53%, ranking among the top declines in concept sectors, with notable drops in stocks such as Pengding Holdings, Industrial Fulian, and Zhongshi Technology [1] Group 1: Market Performance - The top gainers in the market include Changying Precision, Wentai Technology, and Xinwei Communication, with increases of 4.71%, 3.05%, and 0.76% respectively [1] - The concept sectors with the highest gains today include Recombined Protein at 3.72%, Cell Immunotherapy at 3.58%, and Sora Concept (Wensheng Video) at 3.51% [2] Group 2: Capital Flow - The Tonghuashun Fruit Index concept saw a net outflow of 5.675 billion yuan, with 16 stocks experiencing net outflows, and 9 stocks seeing outflows exceeding 1 billion yuan [2] - Industrial Fulian led the net outflow with 3.028 billion yuan, followed by Luxshare Precision, Changdian Technology, and Dongshan Precision with outflows of 1.477 billion yuan, 588 million yuan, and 353 million yuan respectively [2] - The stocks with the highest net inflows include Changying Precision, Wentai Technology, and Xinwei Communication, with inflows of 691 million yuan, 299 million yuan, and 8.716 million yuan respectively [3]

Group 1 - The Hainan Free Trade Zone concept rose by 3.20%, ranking 9th among concept sectors, with 26 stocks increasing in value, including Haima Automobile and Xinlong Holdings hitting the daily limit, and Kangzhi Pharmaceutical, Hainan Development, and Caesar Travel showing significant gains of 17.47%, 8.38%, and 7.55% respectively [1][2] - The concept sector saw a net inflow of 927 million yuan, with 21 stocks receiving net inflows, and 10 stocks exceeding 50 million yuan in net inflow, led by Haima Automobile with a net inflow of 272 million yuan [2][3] - The top stocks by net inflow ratio included Xinlong Holdings, Haima Automobile, and Hainan Haiyao, with net inflow ratios of 33.88%, 28.32%, and 16.73% respectively [3][4] Group 2 - The top gainers in the Hainan Free Trade Zone concept included Haima Automobile, which increased by 10.00% with a turnover rate of 9.05%, and Hainan Development, which rose by 8.38% with a turnover rate of 19.04% [3][4] - The stocks with the largest declines included Jinpan Technology, which fell by 6.52%, and Jingliang Holdings, which decreased by 0.29% [1][4] - The overall performance of the Hainan Free Trade Zone concept indicates strong investor interest and capital inflow, suggesting potential growth opportunities in the sector [2][3]

Core Insights - The monkeypox concept stock increased by 3.20%, ranking 10th among concept sectors, with 69 stocks rising, including notable gainers like Zhongsheng Pharmaceutical and HeFu China, which hit the daily limit [1][2] - The sector saw a net inflow of 1.062 billion yuan, with 46 stocks receiving inflows, and five stocks attracting over 50 million yuan each, led by Zhongsheng Pharmaceutical with a net inflow of 305 million yuan [2][3] Stock Performance - Top gainers in the monkeypox sector included: - Zhongsheng Pharmaceutical: +10.02% with a turnover rate of 10.14% and a net inflow of 304.73 million yuan [3][4] - Asia-Pacific Pharmaceutical: +9.99% with a turnover rate of 21.34% and a net inflow of 258.69 million yuan [3][4] - Other notable performers included Yipin Hong (+9.94%) and Toukeng Life (+8.81%) [1][4] - Decliners in the sector included: - Kefu Medical: -4.35% - *ST Suwu: -1.98% - Jianfeng Group: -1.81% [1][6] Fund Flow Analysis - The top three stocks by net inflow ratio were: - Asia-Pacific Pharmaceutical: 21.24% - Zhongsheng Pharmaceutical: 20.95% - Hainan Hai Pharmaceutical: 16.73% [3][4] - The overall fund flow into the monkeypox concept was significant, indicating strong investor interest [2][3]

Core Viewpoint - The company, Beijing Baipusais Biotechnology Co., Ltd., is experiencing growth in its stock performance and revenue, driven by advancements in cell immunotherapy, recombinant proteins, and its recognition as a "specialized, refined, distinctive, and innovative" enterprise [1][3][9]. Group 1: Company Performance - On October 31, the company's stock rose by 4.25%, with a trading volume of 177 million yuan and a market capitalization of 10.872 billion yuan [1]. - For the first nine months of 2025, the company achieved a revenue of 613 million yuan, representing a year-on-year growth of 32.26%, and a net profit attributable to shareholders of 132 million yuan, up 58.61% year-on-year [9]. - The company has distributed a total of 432 million yuan in dividends since its A-share listing, with 312 million yuan in the last three years [10]. Group 2: Product Development and Market Position - The company has launched a specific antibody targeting the CD19 antigen in CAR-T cell therapy, enhancing detection methods and expanding its product offerings in cell and gene therapy [2]. - It has developed high-quality recombinant proteins for various disease targets, supporting the research and production needs of biopharmaceuticals [2]. - The company is actively developing products related to monkeypox virus, including recombinant proteins and test kits, to aid in vaccine and therapeutic drug development [2]. Group 3: Industry Recognition and Financial Impact - The company has been recognized as a national-level "specialized, refined, distinctive, and innovative" small giant enterprise, which enhances its competitiveness and stability within the industry [3]. - As of the 2024 annual report, overseas revenue accounted for 66.46% of total revenue, benefiting from the depreciation of the yuan [4]. - The company operates in the pharmaceutical and biotechnology sector, specifically in the bioproducts category, and is involved in various concept sectors including financing, artificial intelligence, and mid-cap stocks [9].

Market Overview - Major A-share indices collectively declined, with the Shanghai Composite Index down 0.81% to 3954 points, the Shenzhen Component Index down 1.14%, and the ChiNext Index down 2.31% [1][2] - The total market turnover was 2.35 trillion yuan, a decrease of 114.5 billion yuan compared to the previous trading day, with over 3700 stocks rising and more than 1500 stocks falling [1] Index Performance - Shanghai Composite Index: 3954.79, down 32.11 points (-0.81%) [2] - Shenzhen Component Index: 13378.21, down 153.91 points (-1.14%) [2] - ChiNext Index: 3187.53, down 75.49 points (-2.31%) [2] - STAR Market 50 Index: 1415.53, down 45.77 points (-3.13%) [2] - CSI 300 Index: 4640.67, down 69.24 points (-1.47%) [2] Sector Performance - AI corpus and Kimi concepts saw gains, with stocks like Foxit Software and Rongxin Culture hitting the daily limit [3] - The innovative drug sector surged, with companies such as Shuyitai and Zhongsheng Pharmaceutical also reaching the daily limit [3] - The cultural media sector performed well, with stocks like Huanrui Century and Yue Media hitting the daily limit [3] - Conversely, sectors like HBM concept and storage chips experienced declines, with companies like Shengmei Shanghai and Lanke Technology leading the losses [3] - The CPO concept weakened, with Dekeli dropping over 11%, and the cultivated diamond sector fell, with Power Diamond down over 8% [3]